Lilly’s phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight

In a secondary endpoint, retatrutide demonstrated a mean weight reduction up to 24.2% at 48 weeks Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program INDIANAPOLIS, June 26, 2023 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY)…